Evotec SE ADR (EVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evotec SE ADR (EVO) has a cash flow conversion efficiency ratio of -0.003x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.18 Million) by net assets ($700.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Evotec SE ADR (EVO) total market value for the company's overall valuation and market capitalisation.
Evotec SE ADR - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Evotec SE ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Evotec SE ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evotec SE ADR ranked by their cash flow conversion efficiency. Explore how high is Evotec SE ADR's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chengdu Haoneng Tech Co Ltd
SHG:603809
|
0.000x |
|
Nantong Jiangshan Agrochemical & Chemicals Co Ltd
SHG:600389
|
0.047x |
|
SIGNATUREGLOBAL (INDIA) LIMITED
NSE:SIGNATURE
|
N/A |
|
Air Global PLC Ordinary Shares
NASDAQ:AIIR
|
-0.069x |
|
Netcare
JSE:NTC
|
0.220x |
|
Universal Technical Institute Inc
NYSE:UTI
|
0.030x |
|
ITMAX System Berhad
KLSE:5309
|
0.060x |
|
Atresmedia Corporación de Medios de Comunicación S.A.
MC:A3M
|
0.049x |
Annual Cash Flow Conversion Efficiency for Evotec SE ADR (2003–2025)
The table below shows the annual cash flow conversion efficiency of Evotec SE ADR from 2003 to 2025. View current stock price of Evotec SE ADR for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $813.36 Million | $-9.06 Million | -0.011x | -158.26% |
| 2024-12-31 | $952.52 Million | $18.22 Million | 0.019x | -36.90% |
| 2023-12-31 | $1.12 Billion | $33.95 Million | 0.030x | -82.51% |
| 2022-12-31 | $1.19 Billion | $205.81 Million | 0.173x | +95.39% |
| 2021-12-31 | $1.38 Billion | $122.24 Million | 0.089x | +75.86% |
| 2020-12-31 | $886.41 Million | $44.72 Million | 0.050x | -36.01% |
| 2019-12-31 | $535.47 Million | $42.22 Million | 0.079x | -78.56% |
| 2018-12-31 | $424.88 Million | $156.24 Million | 0.368x | +1026.64% |
| 2017-12-31 | $331.75 Million | $10.83 Million | 0.033x | -89.63% |
| 2016-12-31 | $213.94 Million | $67.36 Million | 0.315x | +276.39% |
| 2015-12-31 | $187.09 Million | $15.65 Million | 0.084x | +448.94% |
| 2014-12-31 | $158.38 Million | $-3.80 Million | -0.024x | -157.25% |
| 2013-12-31 | $158.97 Million | $6.66 Million | 0.042x | -46.57% |
| 2012-12-31 | $152.55 Million | $11.96 Million | 0.078x | +13.75% |
| 2011-12-31 | $147.25 Million | $10.15 Million | 0.069x | +916.62% |
| 2010-12-31 | $132.64 Million | $899.00K | 0.007x | +103.46% |
| 2009-12-31 | $111.49 Million | $-21.85 Million | -0.196x | +28.84% |
| 2008-12-31 | $149.86 Million | $-41.28 Million | -0.275x | -48.33% |
| 2007-12-31 | $170.55 Million | $-31.67 Million | -0.186x | -176.14% |
| 2006-12-31 | $137.18 Million | $-9.22 Million | -0.067x | -367.85% |
| 2005-12-31 | $148.67 Million | $-2.14 Million | -0.014x | +95.23% |
| 2004-12-31 | $61.73 Million | $-18.60 Million | -0.301x | +22.58% |
| 2003-12-31 | $36.03 Million | $-14.02 Million | -0.389x | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more